The Federal Trade Commission has asked for an additional 30 days for its review of Novo Nordisk’s $16.5 billion acquisition ...

A $16.5 billion deal aimed at boosting Novo Nordisk’s production of the weight-loss drug Wegovy is drawing extra scrutiny ...

(Reuters) -The U.S. FTC has sought more information on Novo Nordisk parent's $16.5 billion bid for contract drug manufacturer ...

A bid by the owner of Wegovy maker Novo Nordisk A/S to buy a key manufacturer presents an opening for the US Federal Trade ...

In February, Novo Nordisk agreed to buy Catalent for $16.5 billion. The Federal Trade Commission has since requested more information from the companies as it reviews the deal, The Wall Street Journal ...

The United States Federal Trade Commission (FTC) is seeking more information on Novo Nordisk parent’s $16.5 billion proposed acquisition of Catalent, a US-based contract development manufacturing ...

The FTC’s second request imposes an additional waiting period of up to 30 days for the agency to review the deal from the time the Novo Nordisk Foundation and Catalent submit the required information.

As of 3:50 PM EDT. Market Open. SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide ...

Catalent (NYSE:CTLT) and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission for their planned transaction. Catalent ticked lower by 0.4% in premarket ...

opens new tab has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent (CTLT.N) , opens new tab ...

(Reuters) - The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent. The deal was ...

Novo Nordisk Foundation said last month it had agreed to buy Catalent to boost output of the weight-loss drug Wegovy. After the deal closes, it would sell three of Catalent's fill-finish sites on ...